Metabolic and receptor imaging in patients with neuroendocrine tumors: Comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide

Endocrine Practice

Volumn 15, Issue 6, 2009, Pages 521-527

  Zalom, Martina L ^a   Waxman, Alan D ^a   Yu, Run ^a   Lee, Jessica ^a   Ih, Grace ^a   Wolin, Edward M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; INDIUM 111; OCTREOTIDE; PENTETREOTIDE IN 111; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; FEMALE; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; MALE; MEDICAL RECORD REVIEW; MORBIDITY; NEUROENDOCRINE TUMOR; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDY; SIPPLE SYNDROME; SURVIVAL TIME; COMPARATIVE STUDY; METABOLISM; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICS;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; METABOLIC PHENOMENA; MIDDLE AGED; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 75549092151     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP08318.ORR1     Document Type: Article

References (17)

1. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;340:858-868.
2. Zar N, Garmo H, Holmberg L, Rastad J, Hellman P. Long-term survival of patients with small intestinal carcinoid tumors. World J Surg. 2004;28:1163-1168.
3. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89:151-160.
4. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11:1-18.
5. Chong S, Lee KS, Kim BT, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol. 2007;188:1223-1231.
6. Pasquali C, Rubello D, Sperti C, et al. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg. 1998;22:588-592.
7. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328-333.
8. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295-1300.
9. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003;30:78-84.
10. Choi MY, Lee KM, Chung JK, et al. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer. Ann Nucl Med. 2005;19:123-129.
11. Oudoux A, Salaun PY, Bournaud C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590-4597.
12. Sasaki R, Komaki R, Macapinlac H, et al. [18F] Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136-1143.
13. Delberke D, Martin WH. Update of PET and PET/CT for hepatobiliary and pancreatic malignancies. HPB (Oxford). 2005;7:166-179.
14. Pantaleo MA, Nannini M, Maleddu A, et al. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev. 2008;34:103-121.
15. Berry JD, Cook GJ. Positron emission tomography in oncology. Br Med Bull. 2006;79-80:171-186.
16. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med. 1998;25:639-658.
17. Olsen JO, Pozderac RV, Hinkle G, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med. 1995;25: 251-261.